ema prac naion semaglutide very rare side effect 2025 The use of medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION) Attention Healthcare professionals: WHO Issues

How to Prevent Blindness While Taking Ozempic Other Semaglutide Drugs Linked to Vision Problems Novo Nordisks Response to Ozempic Blindness Allegations New Study Reveals Link Between Ozempic and Blindness from NAION The study linking semaglutide to blindness focused on 16,827 patients, some who were prescribed semaglutide and some of whom were prescribed a different non-glucagon-like peptide receptor antagonist drug for the treatment of diabetes or obesity

The follow-up duration varied among the studies, ranging from 12 months to 68 months, with an average duration of 36 months

Gastrointestinal complaints were most common, including [1, 12]: Indigestion Constipation Nausea Diarrhea Abdominal pain Vomiting These outcomes were dependent on dosage and timing, likely caused by alterations in gastric motility and intestinal uptake

The primary mechanism of action involves mimicking the naturally occurring hormone GLP-1, which is released from the intestine in response to food intake

Lack of official guidance There is currently no standardized or FDA-approved dosing schedule for every-other-week semaglutide use